OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical ...
NANTES, France, Nov. 07, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced a new licensing deal with Chong Kun Dang (CKD) Pharmaceutical Corporation for Tedopi®, a combination of neoepitopes selected and …